CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Akoya Biosciences, Inc. - AKYA CFD

5.64
2.93%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 5.81
Open* 5.76
1-Year Change* -52.36%
Day's Range* 5.6 - 5.79
52 wk Range 3.32-14.38
Average Volume (10 days) 152.48K
Average Volume (3 months) 3.34M
Market Cap 181.08M
P/E Ratio -100.00K
Shares Outstanding 48.94M
Revenue 85.00M
EPS -1.97
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Nov 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 27, 2024 5.81 0.39 7.20% 5.42 5.82 5.40
Feb 26, 2024 5.41 0.11 2.08% 5.30 5.63 5.30
Feb 23, 2024 5.46 0.24 4.60% 5.22 5.69 5.22
Feb 22, 2024 5.32 0.13 2.50% 5.19 5.38 5.19
Feb 21, 2024 5.26 -0.23 -4.19% 5.49 5.64 5.23
Feb 20, 2024 5.61 -0.23 -3.94% 5.84 5.85 5.57
Feb 16, 2024 5.92 0.35 6.28% 5.57 6.03 5.55
Feb 15, 2024 5.78 0.29 5.28% 5.49 5.87 5.49
Feb 14, 2024 5.47 0.01 0.18% 5.46 5.52 5.32
Feb 13, 2024 5.37 -0.12 -2.19% 5.49 5.71 5.29
Feb 12, 2024 5.90 0.01 0.17% 5.89 6.17 5.82
Feb 9, 2024 6.03 0.09 1.52% 5.94 6.10 5.83
Feb 8, 2024 5.90 -0.04 -0.67% 5.94 6.07 5.84
Feb 7, 2024 5.95 0.10 1.71% 5.85 6.00 5.70
Feb 6, 2024 5.95 0.46 8.38% 5.49 6.04 5.35
Feb 5, 2024 5.53 0.04 0.73% 5.49 5.53 5.35
Feb 2, 2024 5.68 0.29 5.38% 5.39 5.68 5.24
Feb 1, 2024 5.53 0.50 9.94% 5.03 5.54 4.94
Jan 31, 2024 5.05 0.16 3.27% 4.89 5.15 4.89
Jan 30, 2024 4.92 -0.02 -0.40% 4.94 5.02 4.81

Akoya Biosciences, Inc. Events

Time (UTC) Country Event
Monday, March 4, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Akoya Biosciences Inc Earnings Release
Q4 2023 Akoya Biosciences Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

22:00

Country

US

Event

Q4 2023 Akoya Biosciences Inc Earnings Call
Q4 2023 Akoya Biosciences Inc Earnings Call

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Akoya Biosciences Inc Earnings Release
Q1 2024 Akoya Biosciences Inc Earnings Release

Forecast

-

Previous

-
Friday, May 31, 2024

Time (UTC)

15:00

Country

US

Event

Akoya Biosciences Inc Annual Shareholders Meeting
Akoya Biosciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 74.859 54.917 42.443 42.236
Revenue 74.859 54.917 42.443 42.236
Cost of Revenue, Total 31.469 20.699 16.535 17.573
Gross Profit 43.39 34.218 25.908 24.663
Total Operating Expense 140.965 91.739 56.125 54.539
Selling/General/Admin. Expenses, Total 79.653 51.016 23.982 26.351
Research & Development 23.211 15.701 9.603 8.761
Depreciation / Amortization 6.734 4.726 3.815 3.055
Unusual Expense (Income) 0 -2.476 1.671 0
Other Operating Expenses, Total -0.102 2.073 0.519 -1.201
Operating Income -66.106 -36.822 -13.682 -12.303
Interest Income (Expense), Net Non-Operating -3.777 -3.115 -2.723 -1.881
Other, Net -0.635 -3.138 -0.259 -0.373
Net Income Before Taxes -70.518 -43.075 -16.664 -14.557
Net Income After Taxes -70.641 -42.935 -16.706 -14.751
Net Income Before Extra. Items -70.641 -42.935 -16.706 -14.751
Net Income -70.641 -42.935 -16.706 -14.751
Total Adjustments to Net Income 0 -1.435 -5.056 -3.556
Income Available to Common Excl. Extra. Items -70.641 -44.37 -21.762 -18.307
Income Available to Common Incl. Extra. Items -70.641 -44.37 -21.762 -18.307
Diluted Net Income -70.641 -44.37 -21.762 -18.307
Diluted Weighted Average Shares 37.7469 26.897 35.6893 35.6893
Diluted EPS Excluding Extraordinary Items -1.87144 -1.64963 -0.60976 -0.51295
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.87144 -1.70946 -0.57933 -0.51295
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 23.521 21.41 21.219 18.852 17.894
Revenue 23.521 21.41 21.219 18.852 17.894
Cost of Revenue, Total 11.405 9.117 9.173 7.945 7.553
Gross Profit 12.116 12.293 12.046 10.907 10.341
Total Operating Expense 42.763 38.846 38.81 35.505 34.202
Selling/General/Admin. Expenses, Total 22.708 21.758 20.948 19.922 20.59
Research & Development 6.273 5.773 6.433 5.466 5.598
Depreciation / Amortization 1.847 1.971 1.759 1.815 1.617
Unusual Expense (Income) 0 0 0
Other Operating Expenses, Total 0.53 0.227 0.497 0.357 -1.156
Operating Income -19.242 -17.436 -17.591 -16.653 -16.308
Interest Income (Expense), Net Non-Operating -1.438 -1.289 -1.07 -1.109 -0.849
Other, Net -0.105 -0.048 -0.24 -0.089 -0.232
Net Income Before Taxes -20.785 -18.773 -18.901 -17.851 -17.389
Net Income After Taxes -20.803 -18.802 -18.875 -17.872 -17.495
Net Income Before Extra. Items -20.803 -18.802 -18.875 -17.872 -17.495
Net Income -20.803 -18.802 -18.875 -17.872 -17.495
Total Adjustments to Net Income 0 0 0
Income Available to Common Excl. Extra. Items -20.803 -18.802 -18.875 -17.872 -17.495
Income Available to Common Incl. Extra. Items -20.803 -18.802 -18.875 -17.872 -17.495
Diluted Net Income -20.803 -18.802 -18.875 -17.872 -17.495
Diluted Weighted Average Shares 40.6397 38.326 38.0052 37.9008 37.6123
Diluted EPS Excluding Extraordinary Items -0.51189 -0.49058 -0.49664 -0.47155 -0.46514
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.51189 -0.49058 -0.49664 -0.47155 -0.46514
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 112.197 140.814 28.696 40.874
Cash and Short Term Investments 81.218 113.079 17.006 21.659
Cash & Equivalents 74.229 113.079 17.006 11.636
Short Term Investments 6.989 0 10.023
Total Receivables, Net 9.729 9.444 6.47 13.167
Accounts Receivable - Trade, Net 9.729 9.444 6.47 13.167
Total Inventory 14.486 9.014 4.263 4.093
Prepaid Expenses 6.764 9.277 0.957 1.955
Total Assets 176.031 190.907 77.66 89.413
Property/Plant/Equipment, Total - Net 24.533 10.035 7.022 5.458
Property/Plant/Equipment, Total - Gross 33.227 15.288 9.802 6.543
Accumulated Depreciation, Total -8.694 -5.253 -2.78 -1.085
Goodwill, Net 18.262 18.262 18.262 18.262
Intangibles, Net 20.048 21.15 22.714 24.137
Other Long Term Assets, Total 0.991 0.646 0.966 0.682
Total Current Liabilities 37.055 27.682 17.162 21.155
Accounts Payable 10.628 9.435 5.074 8.119
Accrued Expenses 17.819 12.284 5.425 6.038
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.62 0.272 1.229 0.08
Other Current Liabilities, Total 7.988 5.691 5.434 6.918
Total Liabilities 117.45 69.556 59.579 55.225
Total Long Term Debt 63.952 32.668 33.765 24.671
Long Term Debt 63.277 32.471 33.488 24.466
Capital Lease Obligations 0.675 0.197 0.277 0.205
Deferred Income Tax 0.087 0.026 0.17 0.163
Other Liabilities, Total 16.356 9.18 8.482 9.236
Total Equity 58.581 121.351 18.081 34.188
Redeemable Preferred Stock 0 69.107 64.347
Preferred Stock - Non Redeemable, Net 0 1.253 1.253
Common Stock 0.002 0.002 0.001 0.001
Additional Paid-In Capital 225.333 217.456 0 0
Retained Earnings (Accumulated Deficit) -166.748 -96.107 -52.28 -31.413
Total Liabilities & Shareholders’ Equity 176.031 190.907 77.66 89.413
Total Common Shares Outstanding 38.2882 37.4241 35.6893 35.6893
Other Equity, Total -0.006
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 116.948 126.17 91.674 112.197 111.744
Cash and Short Term Investments 78.595 93.328 60.247 81.218 81.704
Cash & Equivalents 78.595 93.328 60.247 74.229 51.836
Total Receivables, Net 16.096 12.866 12.943 9.729 8.68
Accounts Receivable - Trade, Net 16.096 12.866 12.943 9.729 8.68
Total Inventory 18.752 16.131 14.507 14.486 13.063
Prepaid Expenses 3.505 3.845 3.977 6.764 8.297
Total Assets 177.244 188.879 154.297 176.031 176.457
Property/Plant/Equipment, Total - Net 22.927 24.304 23.869 24.533 25.367
Property/Plant/Equipment, Total - Gross 34.87 35.159 33.648 33.227 33.051
Accumulated Depreciation, Total -11.943 -10.855 -9.779 -8.694 -7.684
Goodwill, Net 18.262 18.262 18.262 18.262 18.262
Intangibles, Net 18.123 19.125 19.496 20.048 20.442
Other Long Term Assets, Total 0.984 1.018 0.996 0.991 0.642
Total Current Liabilities 35.523 37.39 33.223 37.055 31.682
Accounts Payable 11.89 11.732 8.683 10.628 8.172
Accrued Expenses 12.631 13.912 13.927 17.819 15.746
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.799 0.822 0.608 0.62 0.593
Other Current Liabilities, Total 10.203 10.924 10.005 7.988 7.171
Total Liabilities 115.271 116.978 112.173 117.45 101.369
Total Long Term Debt 64.732 64.702 63.994 63.952 53.406
Long Term Debt 63.818 63.636 63.455 63.277 52.714
Capital Lease Obligations 0.914 1.066 0.539 0.675 0.692
Deferred Income Tax 0.087 0.087 0.087 0.087 0.125
Other Liabilities, Total 14.929 14.799 14.869 16.356 16.156
Total Equity 61.973 71.901 42.124 58.581 75.088
Redeemable Preferred Stock
Preferred Stock - Non Redeemable, Net
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 281.24 278.252 227.672 225.333 223.025
Retained Earnings (Accumulated Deficit) -219.269 -206.353 -185.55 -166.748 -147.873
Total Liabilities & Shareholders’ Equity 177.244 188.879 154.297 176.031 176.457
Total Common Shares Outstanding 49.0624 48.8219 38.3991 38.2882 37.9478
Total Preferred Shares Outstanding
Short Term Investments 0 0 0 6.989 29.868
Other Equity, Total 0 0 0 -0.006 -0.066
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -70.641 -42.935 -16.706 -14.751
Cash From Operating Activities -53.496 -36.068 -6.843 -13.776
Cash From Operating Activities 7.149 4.792 3.815 3.055
Deferred Taxes 0.035 -0.155 0.007 0.156
Non-Cash Items 7.797 6.791 3.647 -0.859
Changes in Working Capital 2.164 -4.561 2.394 -1.377
Cash From Investing Activities -14.079 -5.094 6.728 -12.892
Capital Expenditures -7.36 -5.094 -3.295 -2.869
Other Investing Cash Flow Items, Total -6.719 0 10.023 -10.023
Cash From Financing Activities 28.726 137.035 5.486 28.561
Financing Cash Flow Items -2.35 136.963 -4.421 -1.226
Issuance (Retirement) of Stock, Net 0.447 0.394 0.122 24.828
Issuance (Retirement) of Debt, Net 30.629 -0.322 9.785 4.959
Net Change in Cash -38.849 95.873 5.371 1.893
Cash Interest Paid 3.477 2.668
Cash Taxes Paid 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.802 -70.641 -51.766 -33.894 -16.399
Cash From Operating Activities -19.758 -53.496 -43.489 -31.318 -17.932
Cash From Operating Activities 2.121 7.149 5.248 3.309 1.619
Deferred Taxes 0 0.035 0.099 0.099 0.01
Non-Cash Items 2.834 7.797 5.014 2.493 1.85
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 1.793 3.477 2.189 1.29 0.638
Changes in Working Capital -5.911 2.164 -2.084 -3.325 -5.012
Cash From Investing Activities 6.196 -14.079 -36.21 -43.476 -1.138
Capital Expenditures -0.804 -7.36 -6.491 -2.702 -1.138
Other Investing Cash Flow Items, Total 7 -6.719 -29.719 -40.774
Cash From Financing Activities -0.419 28.726 18.456 8.596 -0.071
Financing Cash Flow Items -0.329 -2.35 -1.345 -1.307
Issuance (Retirement) of Stock, Net 0.058 0.447 0.259 0.219 0.055
Issuance (Retirement) of Debt, Net -0.148 30.629 19.542 9.684 -0.126
Net Change in Cash -13.981 -38.849 -61.243 -66.198 -19.141
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Telegraph Hill Partners Private Equity 32.029 15675247 0 2023-03-31 LOW
Blue Water Life Science Advisors, LLC Investment Advisor/Hedge Fund 9.5989 4697785 2600000 2023-06-30 LOW
Piper Sandler Merchant Banking Fund II, L.P. Corporation 5.5523 2717360 -96411 2022-12-31
aMoon Fund Venture Capital 5.1082 2500000 2500000 2023-06-12 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 3.0965 1515470 200000 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.6749 1309130 321357 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.2263 1089548 171796 2023-06-30 LOW
Winkler (Matthew) Individual Investor 2.0116 984513 203388 2023-06-12
Stanford Management Company Endowment Fund 1.2677 620434 1 2023-06-30
Nolan (Garry P) Individual Investor 1.2605 616913 28612 2023-03-31 LOW
Uniplan Investment Counsel, Inc. Investment Advisor 1.1099 543216 78012 2023-06-30 LOW
SVB Wealth LLC Investment Advisor 1.0529 515317 15400 2023-09-30 LOW
Millennium Management LLC Hedge Fund 1.0361 507069 386429 2023-06-30 HIGH
Granahan Investment Management, Inc. Investment Advisor 0.9853 482196 -114923 2023-06-30 LOW
Parkman Healthcare Partners LLC Hedge Fund 0.9624 471000 269615 2023-06-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7491 366616 44577 2023-06-30 LOW
Pura Vida Investments, LLC Hedge Fund 0.7372 360789 360789 2023-06-30 HIGH
RTW Investments L.P. Investment Advisor/Hedge Fund 0.6915 338422 10000 2023-06-30 LOW
UniSuper Limited Pension Fund 0.6738 329756 329756 2023-06-30 LOW
Kennedy Capital Management, Inc. Investment Advisor 0.613 300023 300023 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Akoya Biosciences, Inc. Company profile

About Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company. The Company deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. It provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. It offers contract research services laboratory, which is called as advanced biopharma solutions.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Akoya Biosciences Inc revenues increased 29% to $54.9M. Net loss applicable to common stockholders increased from $21.8M to $44.4M. Revenues reflect Consumables segment increase of 68% to $14.3M, Instruments segment increase of 21% to $28.7M, North America segment increase of 39% to $28M, EMEA segment increase of 21% to $14.4M. Higher net loss reflects Selling.

Industry: Advanced Medical Equipment & Technology (NEC)

100 Campus Drive
6th Floor
MARLBOROUGH
MASSACHUSETTS 01762
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Gold

2,036.03 Price
+0.290% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

61,361.65 Price
+8.090% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

78.28 Price
-0.100% 1D Chg, %
Long position overnight fee 0.0219%
Short position overnight fee -0.0439%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,862.90 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading